Efficacy of Oral Cytarabine Ocfosfate and Etoposide in the Treatment of Elderly Patients with Higher-Risk Myelodysplastic Syndromes Compared to That in Elderly Acute Myeloid Leukemia Patients

Author:

Horikoshi Akira,Iriyama Noriyoshi,Hirabayashi Yukio,Kodaira Hitomi,Matsukawa Yoshihiro,Uchino Yoshihito,Takahashi Hiromichi,Hatta Yoshihiro,Takeuchi Jin,Kobayashi Sumiko,Miura Katsuhiro

Abstract

<b><i>Background:</i></b> Elderly acute myeloid leukemia (AML) patients and patients with higher-risk myelodysplastic syndromes (MDS) have a much poorer prognosis than younger patients despite intensive chemotherapy. <b><i>Methods:</i></b> Ten patients with higher-risk MDS and 12 patients with AML over 65 years of age were enrolled into this study and received oral induction therapy with cytarabine ocfosfate and etoposide. <b><i>Results:</i></b> The therapy response rates were 60% in the MDS group and 41.7% in the AML group. The difference in overall survival among MDS and AML patients was not statistically significant. The difference in the median survival times of the responsive and nonresponsive groups, which included MDS and AML patients, was statistically significant (790 and 174 days, respectively). <b><i>Conclusions:</i></b> Based on a comparison of the data of this therapy in elderly higher-risk MDS patients versus elderly AML patients, we conclude that this therapy is well tolerated and can be cost-effective and useful for higher-risk MDS in elderly patients.

Publisher

S. Karger AG

Reference23 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3